106 articles on gene editing and biotech
Gene editing is transforming cancer treatment — from CRISPR-enhanced CAR-T cells that achieved 82% remission in leukemia to in vivo approaches that reprogram immune cells directly inside the body. Here's the complete landscape.
97% of patients attack-free for 3+ years from a single IV infusion. Intellia's lonvo-z could be the first in vivo CRISPR therapy approved — transforming gene editing from a transplant procedure into a simple injection.
CRISPR Therapeutics is engineering gene-edited stem cells that produce insulin without triggering immune rejection — potentially ending the need for daily injections for 8.7 million people with Type 1 diabetes.
300 million people worldwide live with a rare disease, and 80% are genetic. Gene therapy and gene editing are offering hope where none existed — but access remains the biggest challenge.
Your blood tells a story about how fast you're aging. From hsCRP to HbA1c to GlycanAge, here are the key biomarkers longevity researchers actually track — and what you can do about them.
The battle over CRISPR patents between the Broad Institute and UC Berkeley is one of the most consequential IP fights in biotech history. Here's who won, what it means, and why it matters.
70,000 people worldwide live with cystic fibrosis. Trikafta transformed treatment, but it's not a cure and doesn't work for everyone. Gene editing could change that — with prime editing achieving 58% correction of the F508del mutation in lung cells.
A complete, up-to-date list of every FDA-approved gene therapy and cell therapy — from Kymriah (2017) to the latest 2025 approvals. Includes pricing, indications, and approval dates.
CRISPR isn't just for editing genes — it's becoming the fastest, cheapest way to detect diseases. From COVID to cancer, here's how SHERLOCK and DETECTR work.
Gene therapies cost $850,000 to $4.25 million per patient. Here's exactly what each therapy costs, who pays, how insurance works, and why some therapies are failing commercially despite curing diseases.
APOE4 is the strongest genetic risk factor for Alzheimer's. What if we could edit it to the protective APOE2 variant? Researchers are working on exactly that — and the early results are promising.
Two gene therapies for sickle cell disease were approved on the same day. One uses CRISPR. The other uses gene addition. Here's how Casgevy and Lyfgenia compare — and why one company is failing.